vs
Side-by-side financial comparison of Primis Financial Corp. (FRST) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $45.6M, roughly 1.7× Primis Financial Corp.). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 13.0%).
Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
FRST vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $45.6M | $75.5M |
| Net Profit | $7.3M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 16.0% | — |
| Revenue YoY | — | 27.7% |
| Net Profit YoY | 200.0% | — |
| EPS (diluted) | $0.30 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.6M | — | ||
| Q4 25 | $80.9M | $75.5M | ||
| Q3 25 | $41.0M | $54.5M | ||
| Q2 25 | $43.2M | $52.4M | ||
| Q1 25 | $58.7M | $46.0M | ||
| Q4 24 | $38.8M | $59.1M | ||
| Q3 24 | $37.3M | $80.5M | ||
| Q2 24 | $35.7M | $47.1M |
| Q1 26 | $7.3M | — | ||
| Q4 25 | $29.5M | — | ||
| Q3 25 | $6.8M | $8.8M | ||
| Q2 25 | $2.4M | $5.9M | ||
| Q1 25 | $22.6M | $3.0M | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $1.2M | $20.3M | ||
| Q2 24 | $3.4M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | — | — | ||
| Q4 25 | 44.8% | 22.7% | ||
| Q3 25 | 21.3% | 17.6% | ||
| Q2 25 | 6.9% | 12.7% | ||
| Q1 25 | 41.9% | 8.7% | ||
| Q4 24 | -123.0% | 22.6% | ||
| Q3 24 | -3.1% | 27.4% | ||
| Q2 24 | 7.8% | -4.6% |
| Q1 26 | 16.0% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 16.7% | 16.2% | ||
| Q2 25 | 5.6% | 11.2% | ||
| Q1 25 | 38.6% | 6.5% | ||
| Q4 24 | -100.3% | — | ||
| Q3 24 | 3.3% | 25.2% | ||
| Q2 24 | 9.6% | -9.6% |
| Q1 26 | $0.30 | — | ||
| Q4 25 | $1.19 | $0.26 | ||
| Q3 25 | $0.28 | $0.17 | ||
| Q2 25 | $0.10 | $0.12 | ||
| Q1 25 | $0.92 | $0.06 | ||
| Q4 24 | $-0.95 | $0.40 | ||
| Q3 24 | $0.05 | $0.41 | ||
| Q2 24 | $0.14 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.9M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $427.2M | $130.3M |
| Total Assets | $4.3B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $159.9M | — | ||
| Q4 25 | $143.6M | $97.5M | ||
| Q3 25 | $63.9M | $94.4M | ||
| Q2 25 | $94.1M | $96.0M | ||
| Q1 25 | $57.0M | $93.2M | ||
| Q4 24 | $64.5M | $101.0M | ||
| Q3 24 | $77.3M | $96.7M | ||
| Q2 24 | $66.6M | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | $427.2M | — | ||
| Q4 25 | $422.9M | $130.3M | ||
| Q3 25 | $382.2M | $115.3M | ||
| Q2 25 | $376.4M | $104.7M | ||
| Q1 25 | $375.6M | $97.1M | ||
| Q4 24 | $351.8M | $92.1M | ||
| Q3 24 | $381.0M | $71.1M | ||
| Q2 24 | $376.0M | $48.5M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.0B | $216.3M | ||
| Q3 25 | $4.0B | $202.9M | ||
| Q2 25 | $3.9B | $194.9M | ||
| Q1 25 | $3.7B | $196.2M | ||
| Q4 24 | $3.7B | $213.3M | ||
| Q3 24 | $4.0B | $220.7M | ||
| Q2 24 | $4.0B | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $10.8M | $14.4M | ||
| Q3 25 | $-11.4M | $9.7M | ||
| Q2 25 | $-41.0M | $14.1M | ||
| Q1 25 | $34.4M | $3.6M | ||
| Q4 24 | $19.5M | $15.6M | ||
| Q3 24 | $6.1M | $11.0M | ||
| Q2 24 | $52.3M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0M | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | $18.3M | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 11.2% | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | 47.3% | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 3.1% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.36× | — | ||
| Q3 25 | -1.67× | 1.10× | ||
| Q2 25 | -16.82× | 2.41× | ||
| Q1 25 | 1.52× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.93× | 0.54× | ||
| Q2 24 | 15.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
PBYI
Segment breakdown not available.
